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ABSTRACT 
Neurotransmitters are low-molecular weight compounds that chemically transfer the 
electrical impulse from one neuron to another and are responsible for the normal 
functioning of the brain. Disturbed balance of neurotransmitters is observed in many 
neurological  disorders,  such  as  Parkinson’s  and  Alzheimer’s  diseases,  and  therefore  the  
measurement of neurotransmitters in the brain is needed to understand how these diseases 
develop and how they can be treated. Neurotransmitters can be extracted from the brains 
of freely moving, alert animals by microdialysis technique. However, the concentration of 
neurotransmitters and their metabolites in brain microdialysates is low, and therefore 
highly sensitive and specific analytical methods are needed. The aim of this study was to 
develop such liquid chromatography-electrospray ionization-tandem mass spectrometric 
(LC-ESI-MS/MS) methods for the analysis of rat or mouse brain microdialysates.  
 
The perfusion fluid used in the microdialysis contains a high concentration of inorganic 
salts (150 mM), whereas the concentration of polar neurotransmitters is low, making 
demands on chromatographic separation. The inorganic salts cause a suppression effect in 
ESI, and therefore they must be separated from the analytes to achieve maximal sensitivity 
of the MS detection. Compounds having the same mass and similar structures as the 
analytes studied are coextracted from the brain, and these must be separated from each 
other to ensure specific analysis. In the present study the analytical methods were 
developed for different chemical classes of neurotransmitters, such as amino acids, 
acetylcholine (Ach) and biogenic amines and their metabolites.  
 
?-Aminobutyric acid (GABA) is the predominant inhibitory neurotransmitter in the brain 
and its concentration in brain microdialysates is low (nM level). However, ESI sensitivity 
is  not  optimal  for  small  and  polar  compounds,  such  as  GABA,  and  in  addition  the  
separation of amino acids from the suppressive salts of the perfusion fluid is problematic. 
In this study, amino acids were derivatized to enhance their ionization and retention in 
reversed-phase chromatography. Three different commonly used derivatization reagents 
(propyl chloroformate (PrCF), butanol and 9-fluorenylmethyl chloroformate (FMOC)) 
were compared in the analysis of amino acids by LC-MS/MS. The limits of detection 
(LODs) for all amino acid derivatives were 2–60 times lower than for native underivatized 
amino  acids.  The  adequate  separation  of  amino  acids  from  the  inorganic  salts  of  the  
perfusion fluid was achieved only after PrCF- and FMOC- but not after butanol 
derivatization. Of the derivatization reagents tested, PrCF was best suited for the analysis 
of amino acids by LC-MS/MS, and PrCF-derivatized GABA and nine other amino acids 
could be easily quantified in rat brain microdialysates. This was the first time that GABA 
was analysed in rat brain microdialysates by specific LC-MS/MS. 
 
The concentration of Ach in brain microdialysates is low (a few nM). Therefore, in some 
studies acetylcholinesterase inhibitors have been used to prevent the metabolism of Ach in 
the brain, and thereby the concentration of Ach in the microdialysate is increased. 
However, the use of inhibitors is not desirable, since they affect neuronal activity and 
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distort the natural chemical balance in the brain. In this study, hydrophilic interaction 
liquid chromatography (HILIC) was utilized in the analysis of Ach and choline (Ch). Ach 
and Ch showed good retention in the polar diol stationary phase used in HILIC and they 
were eluted at high (80%) concentration of acetonitrile (ACN) in the eluent, which is 
favourable to ESI and enabled sensitive analysis of Ach. The limit of quantification (LOQ) 
for Ach was 0.1 nM, which allowed the analysis of Ach in rat and mouse brain 
microdialysates without the use of acetylcholinesterase inhibitors.  
 
Neurotransmitters  and  their  phase  I  metabolites  are  also  known  to  undergo  phase  II  
metabolism in the brain. However, glucuronide and sulfate conjugates have not been 
studied in brain microdialysates and only nonspecific indirect analytical methods 
employing acid or enzyme hydrolysis have been used in the analysis of cerebrospinal fluid 
(CSF) and brain samples. Here sulfate and glucuronide conjugates of dopamine (DA), 
serotonin (5-HT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) 
and 5-hydroxyindoleacetic acid (5-HIAA) were synthesized enzymatically or chemically 
for reference compounds. LC-MS/MS methods for the analysis of intact sulfate and 
glucuronide conjugates in rat and mouse brain microdialysates were developed. The 
methods enabled detection of the different regioisomers of the conjugates, which has not 
been possible with indirect methods. In the present study, the glucuronidation of the 
neurotransmitters 5-HT and DA in the brain was shown for the first time. The 
neurotransmitters were glucuronidated while their acidic phase I metabolites were 
sulfated. 
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LOQ limit of quantification 
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1. INTRODUCTION 
There are about 100 billion nerve cells in the human brain and over 99% of the 
communication between neurons is based on chemicals called neurotransmitters [1]. 
Neurons vary in shape and size, but basically a neuron has a cell body with two types of 
projections: dendrites bringing information to the cell body and an axon carrying the 
information from the cell body. When electrical impulses arrive at the nerve ending, 
neurotransmitters are released from the presynaptic neuron to a synaptic cleft, a 
microenvironment between neurons, and they bind to specific receptors of the 
postsynaptic neuron. The binding either activates, producing an electrical impulse, or 
deactivates, hindering the formation of electrical impulses in the postsynaptic neuron. In 
other words, the electrical impulse from one neuron to another is chemically signalled by 
neurotransmitters. To terminate the signal, neurotransmitters are enzymatically inactivated 
or they are transferred from the synaptic cleft by active uptake mechanisms. The 
neurotransmitters taken back to the presynaptic neuron are either metabolized or restored 
for a new neurotransmission process. Molecules with different structures function as 
neurotransmitters, and they are divided into different chemical classes such as biogenic 
amines, peptides and amino acids. Neurotransmitters are responsible for the functioning of 
the central nervous system (CNS); mood, thought, learning, and memory, for example. 
Disturbed balance of neurotransmitters in the brain has been observed in various 
neurological  disorders,  such  as  Parkinson’s  disease  [2],  Alzheimer’s  disease  [3],  and  
schizophrenia [4]. Understanding of brain functioning in normal and diseased states is 
essential  to  the  development  of  treatment  strategies,  and  knowledge  of  where  
neurotransmitters are released and at what rate is desired. However, sampling from the 
brain is challenging. A microdialysis technique has been used for the extraction of 
neurotransmitters from freely moving and alert animals. The concentration of 
neurotransmitters in brain microdialysates (MDs) is then measured, either on-line or off-
line. However, the concentrations are low and thus highly sensitive and specific analytical 
methods are needed in the area of brain research. 
1.1 Neurotransmission 
Neurotransmitters can be divided according to their chemical structure into 
catecholamines, amino acids, indoleamines, neuropeptides and acetylcholine (Ach). The 
chemical signalling differs among neurotransmitters, and the speed of synaptic signal 
transmission  is  either  fast  (below  1  ms)  or  slow  (from  hundreds  of  milliseconds  to  
minutes) [1]. The rapid transmission operates through ligand-operated ion channel 
receptors (ionotropic channels) that allow the flow of chloride, sodium, potassium or 
calcium ions into the postsynaptic neuron. The inside of the neuron is more negatively 
charged than the outside. The binding of an excitatory neurotransmitter into the ion 
channel causes the flow of positive ions into the postsynaptic neuron, which is then 
depolarized. If the depolarization is high enough, an action potential is formed and a rapid 
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electrical  impulse  travels  down the  neuron.  Half  of  all  the  fast  synapses  in  the  brain  are  
excitatory and the main neurotransmitter is the amino acid glutamic acid (Glu). Another 
amino acid, ?-aminobutyric acid (GABA), is mainly responsible for fast inhibitory 
transmission and the binding of GABA opens an ion-channel, which allows the chloride 
ions to flow inside the cell. The neuron is hyperpolarized and the formation of electrical 
pulses in the postsynaptic neuron is hindered. Synaptic transmission is slow in the 
majority of neurotransmitters, including GABA and Glu, when they bind to the G-protein-
coupled receptor (metabotropic receptor). Binding activates secondary messengers, which 
in turn activate distinct classes of protein kinases. The consequence of these complex 
cascades is the control of production of fast- and slow-acting receptors and ion pumps that 
restore the ionic equilibrium after hyperpolarization or depolarization. Slow synaptic 
transmission also affects transcription factors in the cell nucleus, resulting in long-term 
changes in the nerve cell that are likely needed in learning and memory processes. 
 
Signalling between neurons does not always occur in a way that neurotransmitters are 
released from the axon terminals of the presynaptic neuron and alter the signalling of the 
postsynaptic neuron. Compounds, such as nitric oxide and lipid derivatives (anandamide, 
2-arachnoidyl glycerol), have been identified in the brain where they act as retrograde 
messengers that are released from the postsynaptic neuron and control presynaptic activity 
[5]. The “common neurotransmitters” can also be released nonsynaptically from localized 
axonal  swellings  and  diffuse  to  the  site  of  activity  in  the  extracellular  space.  
Neuropeptides, for one, are released almost from the entire surface of the neuron and they 
diffuse to the site of activity through the extracellular space. Neuropeptides are from 3 to 
100 amino acid residues long, and their signalling specificity is based on high binding 
affinity for their receptors. The neural activity aroused by neurotransmitters can also be 
modified by other compounds such as neuroactive steroids [6, 7]. Neuroactive steroids 
may be synthesized in the brain or periphery, and among their many targets are the amino 
acid  receptors,  but  they  bind  to  different  sites  than  the  actual  neurotransmitters.  The  
modulatory effects of different neurosteroids can be inhibitory or excitatory. 
1.1.1 Synthesis and phase I metabolism of neurotransmitters 
In the early 20th century, there was ongoing debate on whether communication between 
neurons was chemical or electrical in nature and Ach was the first neurotransmitter 
identified in the CNS [8]. The synthesis of Ach from choline (Ch) and acetyl-coenzyme A 
is catalysed by choline acetyltransferase in the presynaptic neuron [9, 10]. Ach is stored in 
vesicles, which are fused to the presynaptic membrane of the neuron after the electrical 
impulse, and Ach is released to the synaptic cleft. The activity of Ach is quickly 
terminated by acetylcholinesterase present in membranes of the pre- and postsynaptic 
neurons, and Ach is hydrolysed to Ch and acetate (Fig. 1). Ch is actively taken back to the 
presynaptic neuron for the synthesis of new Ach. Ach is known to be involved in learning, 
memory, temperature and blood pressure regulation. Several diseases are also related to 
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malfunctioning of the cholinergic system, such as Huntington’s, Alzheimer’s and 
Parkinson’s diseases. 
 
 
Figure 1. Metabolism of acetylcholine to choline and acetate by acetylcholinesterase. 
Amino acids are an important and abundant class of neurotransmitters in the brain [11, 
12]. However, they were identified as neurotransmitters much later than Ach and the 
biogenic amines. The most important amino acid neurotransmitters are excitatory Glu and 
aspartic acid (Asp), and inhibitory GABA and glycine (Gly) (Fig. 2). The metabolism of 
excitatory and inhibitory amino acids is closely related. GABA is formed from Glu by an 
enzyme called glutamate decarboxylase. GABA and Glu for one can be metabolized to 
aspartate. The action of GABA and Glu in the synaptic cleft is terminated by uptake to the 
presynaptic neuron or glial cells, which provide support and nutrition for neurons. Glu is 
neurotoxic, which may be why Glu in glial cells is converted to nontoxic glutamine, which 
in turn can be synthesized back to Glu in the presynaptic neurons. In addition to acting as 
a neurotransmitter, Glu is associated with metabolic regulation in the brain, which 
complicates study of the neurotransmitter role of Glu. Glu is associated with learning and 
memory functions of the brain as well as neurological disorders such as cerebral 
ischaemia, hypoxia and epilepsy [12]. Malfunctioning of GABA excretion is observed in 
the pathophysiology of epilepsy and anxiety, and altered concentrations of Gly, Glu, and 
GABA are observed in schizophrenia. 
 
Figure 2. Structure of main inhibitory and excitatory amino acids in central nervous system. 
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Catecholamines, such as dopamine (DA), noradrenaline (NA) and adrenaline (A), are 
synthesized from tyrosine (Tyr) [13]. The rate limiting step is hydroxylation of Tyr to L-
3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase. The formation of DA 
from L-DOPA is catalysed by the aromatic L-amino acid decarboxylase. DA itself acts as 
a  neurotransmitter,  but  it  is  also  a  precursor  for  synthesis  of  NA  (Fig.  3)  [13].  The  
formation of serotonin (5-hydroxytryptamine, 5-HT) begins with hydroxylation of 
tryptophan by tryptophan hydroxylase and is continued by the aromatic L-amino acid 
decarboxylase [14]. The activity of 5-HT and DA in the synaptic cleft is terminated 
mainly by active uptake mechanisms in the presynaptic neurons [15]. Part of the DA and 
5-HT is also metabolized through monoamine oxidase (MAO) and aldehyde 
dehydrogenase catalysed reactions to dihydroxyphenylacetic acid (DOPAC) and 5-
hydroxyindoleacetic acid (5-HIAA), respectively (Fig. 3). DOPAC can be further 
metabolized to homovanillic acid (HVA) by catechol-O-methyltransferase (COMT). The 
major metabolite of NA in the CNS is 3-methoxy-4-hydroxyphenylglycol (MHPG). 5-HT-
excreting neurons are found in almost all brain areas and therefore 5-HT is associated with 
regulation of emotional, feeding and cognitive behaviour, sleep, thermoregulation etc. as 
well as pathological states such as depression, mania, migraine and schizophrenia [14]. 
Catecholamines, especially DA, are involved in attention deficit hyperactivity disorder 
(ADHD),  schizophrenia  and  Parkinson’s  disease  [16].  It  is  also  known  that  DA  plays  a  
central role in the mechanism of action of drugs of abuse.  
1.1.2 Sulfation and glucuronidation of neurotransmitters 
Enzyme-catalysed metabolism is commonly divided into phase I and phase II reactions. A 
small polar functional group is added or exposed in phase I reactions, which include 
oxidation, reduction and hydrolysis. Phase II reactions are called conjugation reactions, in 
which a polar moiety is attached to the molecule. Glucuronidation and sulfonation (more 
commonly called sulfation) are common phase II metabolism reactions (Fig. 4). 
Glucuronidation is catalysed by uridine diphosphoglucuronosyltransferases (UGTs), 
which are membrane-bound enzymes of the endoplastic reticulum [17]. In the reaction the 
glucuronic acid moiety is transferred from the uridine-5’-diphosphoglucuronic acid 
(UDPGA) to a wide variety of compounds that contain hydroxyl, carboxyl, amine or thiol 
groups. UGTs exhibit tissue-specific expression but are mainly expressed in the liver. 
Isoforms of UGTs 1A6, 2A1 and 2B7 have been found in human [18] and UGT1A6 in rat 
brain  [19].  UGTs 1A6 and  2B7 are  known to  catalyse  the  glucuronidation  of  5-HT,  the  
former having a much higher glucuronidation rate than the latter enzyme [20]. So far 
glucuronide conjugates of neurosteroids have been detected in mouse brain [21] and 
dopamine glucuronide (DA-G) in rat [22] and human cerebrospinal fluid (CSF) [23].  
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Figure 3. Structures of biogenic amine neurotransmitters and their metabolites in the central 
nervous system. 
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Sulfation is catalysed by cytosolic sulfotransferase (SULT) enzymes, which are divided 
according to their amino acid sequence and enzyme function into the phenol (SULT1) and 
steroid (SULT2) sulfotransferase families [24]. Most commonly the hydroxyl group of the 
substrate is sulfated and the cosubstrate needed in the reaction is 3’-phosphoadenosine-5’-
phosphosulfate (PAPS). Sulfation of phenols is catalysed by the SULT1 family, and 
SULTs 1A1, 1A2 and 1A3 have been found in the human brain. The isoform SULT1A3, 
existing only in humans and other very close primate relatives, has high selectivity and 
catalytic efficiency for DA. In rat brain the activity of phenol-sulfating SULT is also 
observed [25] and sulfate conjugates of DA [26] and monoamine metabolites, such as 
DOPAC-sulfate (DOPAC-S), HVA-S, MHPG-S and 5-HIAA-S have been detected [27-
29]. Usually metabolism leads to inactivation, but some neurosteroid sulfates are known to 
act as neuromodulators in the brain [30]. The sulfated form may also be exploited in the 
synthesis  of  other  neurotransmitters  as  reported  for  DA-S,  which  is  a  substrate  of  NA-
forming dopamine-?-hydroxylase [31]. 
 
 
 
Figure 4. Enzyme-catalysed glucuronidation and sulfation of HVA. 
 
 
 
 
16 
1.2 Techniques for studying neurotransmission 
Monitoring of chemical changes in the brain is challenging. The aim is to measure the 
concentration of neurotransmitters and their metabolites in local brain areas with high 
sensitivity and specificity. The measurement of changes in concentrations at short time 
intervals is also desired [32]. One way is to analyse neurotransmitters in the brain tissue. 
Typically, a brain sample is homogenized in acid and water-soluble neurotransmitters are 
extracted to the liquid phase [12]. The release and changes in neurotransmitter 
concentrations cannot be measured this way and only a snapshot can be achieved [5]. The 
proportion of extracellular and intracellular neurotransmitters likewise cannot be 
identified, and postmortem changes in the concentrations of neurotransmitters are 
possible.  Samples taken from the CSF better reflect  the release of neurotransmitters,  but 
the concentrations of neurotransmitters provide only a rough temporal estimation of the 
release throughout the entire CNS. Microdialysis and voltammetry provide more localized 
information on brain neurotransmission, and these techniques are mainly used in 
neurochemical monitoring. 
 
In voltammetry a carbon electrode (3 µm in diameter) is inserted into a region of interest 
in the animal brain [33]. Voltammetry is based on oxidation and reduction reactions of 
electroactive  compounds  of  the  brain  at  the  surface  of  the  electrode.  Oxidation  at  a  
specific potential generates a current, whose magnitude is used in the estimation of the 
concentration. However, the differences in oxidation potentials of compounds found in the 
brain are small, complicating the specific analysis. Currently, fast cyclic voltammetry is 
used, in which the potential of the electrode is linearly ramped and compounds having 
slightly different oxidation potentials can be separated. More specificity can also be 
obtained using enzyme-based sensors, in which the enzyme specifically binds the analyte 
studied and the end product of the enzymatic reaction is oxidized at the surface of the 
electrode. The greatest advantage of the voltammetry technique is the high temporal 
resolution of 100 ms or less [34]. 
 
Microdialysis has been widely used in the sampling of neurotransmitters and their 
metabolites in defined brain areas [32, 35, 36]. Even though the temporal resolution is 
lower than in voltammetry, the identity and concentration of neuroactive compounds can 
be more accurately determined by selecting specific analytical techniques for the 
measurement of brain microdialysates. In microdialysis a guide cannula is surgically 
implanted into a region of interest in an animal’s brain. After the animal has recovered 
from the surgery, a semipermeable dialysis membrane is inserted into the guide cannula 
[37]. The sampling is performed on a freely moving, unanaesthetized animal by pumping 
physiological perfusion fluid at a low flow rate (0.5–2.5 µl/min) through the dialysis 
membrane [32, 35, 36]. The low-molecular weight and water-soluble compounds in the 
extracellular fluid of the brain are extracted to the perfusion fluid by passive diffusion 
according to the concentration gradient. The extracellular fluid of the brain contains 
synaptically released neurotransmitters and their metabolites, as well as compounds from 
 
 
 
 
17
nonsynaptic sources [36]. The molecular mass cutoff of membranes varies from 5 to 100 
kilodaltons (kDa),  preventing the entering of proteins into the dialysate.  The recovery of 
compounds is dependent on many variables, such as the temperature, molecular weight 
and charge, flow rate of the perfusion fluid, surface area and material of the dialysis 
membrane etc. [35]. The concentration of neurotransmitters in the extracellular fluid can 
be estimated, but the absolute value for in vivo recovery of compounds in microdialysis is 
difficult to determine. Another disadvantage of the microdialysis technique is that the 
invasive implantation of the microdialysis probe may evoke inflammation [32]. The 
concentration of compounds in microdialysates is also lower than in the extracellular fluid, 
due to the diluting effects of dialysis, making demands on the analytical techniques used 
in the analysis. 
1.3 Analysis of neurotransmitters in brain microdialysates 
The concentration of neurotransmitters in microdialysates is low (in the fmol range) and 
the sample volume is limited (typically < 40 µl) [38, 39]. The perfusion fluid used in 
microdialysis contains a high concentration (150 mM) of inorganic salts, which must be 
separated from polar neurotransmitters to ensure reliable detection and quantification of 
the analytes. Separation of the analytes studied from other endogenous compounds 
coextracted from the brain is also needed. Usually neurotransmitters have been analysed 
by liquid chromatography (LC) connected to electrochemical (EC), fluorescence (FL), 
ultraviolet (UV) or electrospray ionization-mass spectrometric (ESI-MS) detectors. The 
retention of neurotransmitters and their metabolites in reversed-phase chromatography is 
poor and therefore ion-pair chromatography, cation-exchange chromatography, and 
hydrophilic interaction liquid chromatography (HILIC) employing polar stationary phases 
have been used to achieve adequate retention and separation [38, 39]. The separation of 
polar compounds in HILIC is believed to be based on different partitioning of the analyte 
between the hydrophobic eluent and a water-rich liquid layer formed on the polar 
stationary phase. Detection of lower concentrations of neurotransmitters in 
microdialysates has been achieved by downscaling the column diameter [40]. However, 
only the MS of the detectors used provides sufficient specificity in the analysis of 
neurotransmitters, since the analyte is identified by both retention time (rt) and molecular 
weight. Using tandem mass spectrometry (MS/MS), the specific dissociation pathway of 
the molecule is followed, which further increases the specificity, and the limit of detection 
(LOD) is also improved compared with MS detection. Volatile eluents must be used in the 
LC-MS/MS analysis and therefore the nonvolatile concentrated buffers used in ion-
exchange chromatography and nonvolatile ion-pair reagents are not an option. The 
inorganic salts of the perfusion fluid cause ion suppression in the analysis of brain 
microdialysates by LC-ESI-MS/MS and they must be separated from the analytes. Other 
endogenic compounds extracted from the brain may also coelute with the analytes studied 
and alter the ESI process. Therefore possible suppression effects must be studied 
individually for each analyte to ensure reliable quantification. The analytical challenges 
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related to measurements of amino acids, Ach and monoamine neurotransmitters in 
microdialysates are described here in more detail. 
1.3.1 Amino acids 
The concentration of amino acids in microdialysates is much higher (from nM to µM) than 
other neurotransmitters, such as Ach, 5-HT and DA (low nM). There have been 
speculations on whether the concentrations of GABA and Glu, the most often analysed 
amino acids in microdialysates, reflect the neuronal release of these neurotransmitters or 
do the amino acids enter into the extracellular fluid also from non-neuronal sources [41-
43]. Two criteria should be fulfilled, provided the neurotransmitter in the microdialysate 
has originated from neuronal release. The concentration of neurotransmitter in the 
microdialysate should be decreased by 70–90%, when the formation of an action potential 
in the nerve cell is blocked by the Na+-channel blocker tetrodotoxin or the action of Ca2+ 
is blocked by the use of the Ca2+ antagonist Mg2+ or Ca2+-chelating 
ethylenediaminetetraacetic acid. Ca2+ ions under normal conditions flow into the 
presynaptic neuron during the action potential and are needed for the release of 
neurotransmitters into the synaptic cleft. The concentration of DA, 5-HT and Ach is 
clearly decreased after a 10–15 min infusion of tetrodotoxin and these neurotransmitters 
also show a clear response to Ca2+ depletion [42, 43]. However, a statistical difference in 
the concentration level of GABA is seen only 50–80 min after the tetrodotoxin dosage, 
indicating that GABA is at least partly originated from non-neuronal sources [41-43].  
 
Amino acids have been analysed by LC, capillary electrophoresis (CE) and GC [12]. 
Derivatization of nonvolatile amino acids and sample cleaning is required in GC analysis. 
Derivatization is also often employed in the analysis of amino acids by LC and CE to 
enhance the sensitivity of detection. The most commonly used derivatization reagent is o-
phthalaldehyde (OPA), and amino acid derivatives can be detected by FL [44, 45] or EC 
[46, 47]. However, some of the amino acid derivatives formed with OPA are labile [48] 
and therefore naphthalene-2,3-dicarboxaldehyde (NDA), which forms more stabile 
derivatives, has been used in the analysis by CE-laser-induced fluorescence (LIF) [49] and 
LC-FL [50, 51]. Good sensitivity is required from the analytical method so that smaller 
sample volumes can be analysed and thereby the rapid changes in concentration of amino 
acids in the brain can be monitored. In the majority of studies using LC-EC [47, 52, 53] or 
LC-FL [50, 54]  the samples are collected at 5–30-min time intervals (sample volume 2–
30 µl), but a significantly higher sampling rate (10 s, 200 nl sample volume) was reported, 
using capillary LC-amperometry [46]. The fast analysis times achieved with CE (< 20 s) 
has enabled the on-line analysis of amino acids in brain microdialysates [55-57].  
 
The concentrations of GABA reported in the literature have varied greatly (9–170 nM) in 
rat brain striatum microdialysates analysed by LC-EC [47, 52], LC-FL [58] or CE-LIF 
[49, 55, 56, 59]. Rea et al. [58] suggested that one reason for the high variation in GABA 
concentration is the difficulty in separating G??? from the endogenous impurities 
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present in microdialysates with nonspecific analysis methods. Higher specificity can be 
achieved using MS detection but in the study of Ma et al. [60] the LOD (10 µM, 200 
pmol) was too high for the analysis of GABA in rat and mouse brain microdialysates. A 
lower LOD (48 nM, 1 pmol) for GABA by LC-MS/MS was achieved after precolumn 
derivatization with 7-fluoro-4-nitrobenzoxadiazole (NBD-F) [61]. The method was 
applied for the analysis of human plasma and CSF samples in which the concentration of 
GABA was much higher (> 400 nM) than in rat brain microdialysates. A capillary-HILIC-
MS/MS method was used for the quantitative analysis of underivatized GABA sampled 
from monkey brain [62]. Even though the LOD for GABA in the capillary-HILIC-MS/MS 
method was 4 nM (1.2 fmol), the quantitative analysis of rat brain microdialysates might 
be problematic, because five-fold dilution of the microdialysis sample with ACN was 
needed to ensure good chromatographic performance and thereby the lowest detectable 
concentration  of  GABA  in  brain  microdialysate  is  20  nM.  Isomers  of  GABA,  ?-and ?-
ABA,  are  also  coextracted  from  the  brain,  and  the  separation  of  these  compounds  from  
GABA must be taken into account, even when using specific LC-MS/MS [46, 55]. 
1.3.2 Acetylcholine 
Ach is quickly metabolized to Ch and acetate by acetylcholinesterase after release in the 
synaptic cleft and hence the concentration of Ach in the microdialysates is low (0.1–6 nM) 
[63, 64]. Therefore in some studies acetylcholinesterase inhibitors have been used to 
increase the concentration of Ach in the extracellular fluid of the brain [65]. However, the 
inhibitors may affect neuronal activity and alter the effects of different drugs on Ach 
release. To avoid the use of acetylcholinesterase inhibitors, sensitive analytical methods 
for the measurement of Ach have been developed. The concentration of Ch in the 
extracellular fluid is high (0.6–5 µM) [66, 67] and chromatographic separation from Ach 
is needed, especially with nonspecific detectors. 
 
Gas chromatography (GC) has been used for the analysis of Ach in brain samples [9], but 
the analysis of Ach in brain microdialysates has not been possible without the use of  
acetylcholinesterase inhibitors in the perfusion fluid, due to the high LOD of the GC-MS 
method (10-40 nM, 0.5–2 pmol) [68]. The most widely used method for the analysis of 
Ach in microdialysates is LC-EC, and the LODs are low enough (0.2–2 nM, 2–10 fmol) 
for the analysis of brain microdialysates without the use of acetylcholinesterase inhibitors 
[64, 65, 69]. However, better sensitivity and specificity is achieved with LC-ESI-MS/MS, 
the LOD being 0.075–1 fmol (7.5–100 pM) [63, 70, 71], and by using capillary LC 
columns attomol levels (8–15 amol, 40–50 pM) can be achieved [62, 72] (Table 1). 
Furthermore,  LC-MS/MS provides  direct  detection  of  Ach and  Ch,  whereas  when EC is  
used, the analytes must be converted into hydrogen peroxide using enzyme-catalysed 
reactions. Separation of Ach from the inorganic salts of the microdialysis perfusion fluid 
is necessary to avoid suppression effects in ESI and contamination of the ion source. Even 
though MS/MS provides specificity, the chromatography plays an essential role in the 
analysis of Ach, because endogenous compounds having the same mass and similar 
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collision-induced dissociation as Ach and acetyl-?-choline, are extracted from the brain 
[63, 70]. Acetyl-?-choline is commonly used as an internal standard (ISTD). The 
chromatographic separation of these endogenous compounds from Ach and the ISTD is 
clearly needed to guarantee reliable quantification.  
 
Cation-exchange chromatography [70, 72-74] and HILIC [62, 71] are most commonly 
used in the LC-MS/MS analysis of Ach in microdialysates. In cation-exchange 
chromatography concentrated buffers must be used, and they may suppress the ESI 
process. In HILIC, polar stationary phases and aqueous mobile phases containing more 
than 50% organic solvents are used [75]. The high concentration of organic solvent 
facilitates the desolvation and compound ionization in ESI. The use of capillary columns 
has enabled MS/MS detection at the attomol level with both cation-exchange and HILIC 
separation methods [62, 72]. 
 
Ion-pair chromatography has been used in few studies for the analysis of Ach [63, 76]. 
However, the ion-pair reagents, having limited volatility, can contaminate the MS ion 
source and deteriorate the performance of ESI, resulting in low sensitivity and signal drop 
in a short time [39]. Atmospheric-pressure chemical ionization (APCI) is less prone to 
signal suppression than ESI. Since the Ach is positively charged, regardless of the pH (due 
to a quaternary amine group), the APCI source can be used without a discharge current. 
This is called atmospheric-pressure spray ionization (APSI), and it was exploited in a 
recent study, where Ach could be routinely analysed in rat brain microdialysates using 
trifluoroacetic acid in the eluent [77]. The ion pair reagent trifluoroacetic acid causes 
suppression in ESI, whereas in APSI the signal intensity of Ach was even increased.  
1.3.3 Biogenic amines and their metabolites 
The concentrations of biogenic amine neurotransmitters and also their phase I metabolites 
in brain microdialysates are used in determination of the activity of DA-, NA- and 5-HT-
excreting neuronal systems. These neurotransmitters and their metabolites are also known 
to undergo phase II conjugation reactions in the brain: DA-G was detected in rat CSF [22] 
and sulfates of DA, MHPG, 5-HIAA, DOPAC and HVA have been measured in rat brain 
samples [26-29]. The sulfate and glucuronide conjugates in brain have mostly been 
analysed by indirect analysis methods employing acidic [78-84] or enzymatic hydrolysis 
[26-29]. Even though the type of conjugate can be investigated with greater certainty after 
enzyme than after acid hydrolysis, the presence of the conjugate is still difficult to confirm 
by indirect methods, especially if the concentration of the conjugate is low compared with 
that of free aglycone. Few methods are available for the analysis of intact sulfates or 
glucuronides of neuronal compounds, probably due to lack of commercial standards: 
analysis of DA-, NA- and 5-HT-Ss by ion-pair chromatography-EC [85] and  LC-UV-FL 
for the determination of intact 5-HT-G [86]. However, the LODs with these methods may 
be too high for the analysis of brain microdialysates being 50 nM (1 pmol) for DA-, NA-, 
and 5-HT-Ss [85]. 
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DA,  NA,  A  and  5-HT  have  usually  been  analysed  using  LC-EC,  LC-FL,  LC-
chemiluminescence or LC-MS [87]. CE-LIF has been used for the analysis of DA and 5-
HT  in  brain  microdialysates  [88,  89]  and  an  on-line  analysis  of  DA  was  also  presented  
[90]. The retention of polar catecholamines in reversed-phase chromatography is poor and 
therefore ion-pair reagents (alkylsulphonic acids) were used in the eluent to improve 
retention and separation [91]. Cation-exchange chromatography was also used for the 
analysis of biogenic amines in microdialysates [92]. However, these chromatographic 
methods are not preferred for sensitive ESI-MS detection, because nonvolatile ion-pair 
reagents and concentrated buffers are used as eluents. To increase the sensitivity of LC-
MS/MS analysis, volatile eluents such as formic acid (HCOOH) and ammonium acetate 
(NH4Ac) have been used in reversed-phase chromatography [93-95]. Since formate and 
acetate form only weak ion-pairs with biogenic amines, the retention of neurotransmitters 
in reversed-phase chromatography is poorer than with alkylsulphonic acids. Therefore, 
more polar stationary phase, such as polyhydroxyethyl aspartamide [62], has been used to 
enhance retention. 
 
Biogenic amine neurotransmitters are easily oxidized, and therefore they have usually 
been detected by EC. Catecholamines and 5-HT also have native fluorescence, but 
derivatization has been used to improve separation and ensure sensitive detection by LC-
FL (4.2–9.5 pM, 42–96 amol), because the concentrations of these neurotransmitters in 
brain microdialysates are low (fmol amounts) [96]. Higher selectivity is provided by LC-
MS/MS as shown by Hows et al. [93], who analysed rat brain microdialysates by both LC-
EC  and  LC-MS/MS.  The  concentration  of  DA  in  microdialysates  was  5.5  nM  when  
analysed by LC-EC and only 0.47 nM when analysed by LC-MS/MS, indicating that some 
endogenous impurities were interfering in the quantitative analysis with LC-EC. The 
LODs for NA and 5-HT by LC-MS/MS (0.2–1 nM, 2–10 fmol [93]) were too high for 
quantification of the basal levels of these neurotransmitters in rat brain microdialysates. 
Similar LODs were achieved by LC-EC [97], but by using capillary LC-EC the LOD for 
5-HT could be decreased to 84 pM (84 amol) [98]. In a recent study DA, NA and 5-HT 
were derivatized by deuterated acetaldehyde and the LODs (30 pM, 600 amol) were as 
many as 20–100 times lower than those for native neurotransmitters, using 
ultraperformance LC (UPLC?)-MS/MS [99]. With this UPLC?-MS/MS method the 
concentrations of DA, NA and 5-HT could be determined in microdialysates collected 
from the medial prefrontal cortex of rat brain.  
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Table 1. Utilization of mass spectrometry in the analysis of neurotransmitters in the brain. The analyses were carried out in SRM mode unless 
otherwise stated with asterisk (*). 
Amino acids 
Analytes Separation Column Eluents Derivati-
zation 
Ionization Inj.  
[µl] 
LOD (nM) Sample Ref 
GABA, ?-ALA GC* CP-Sil 88  MeCF NCI, NH3  GABA: 5  Human lumbar  
CSF 
[100] 
Amino acids GC* HP-5ms  EtCF EI  Glu: 1 pmol Rat brain [101] 
Amino acids, GABA, 
Glu, Gly, Ser, Cys 
GC* HP-5ms  MTBSTFA PCI (NH3)    Rat brain MD [102] 
D- and L-serine LC C-18 
(2.1?40 mm, 5 µm) 
15 mM NH4Ac 
MeOH:ACN 
Marfey’s  
reagent 
ESI- 50 LLOQ 95 Rat brain  
MD 
[103] 
Ach, 5-HT, DA, 
GABA, Glu, Asp 
Cap-LC HILIC 
(polyhydroxyethyl 
aspartamide) 
(0.2?300 mm) 
20  mM  NH4form + 1% 
HCOOH 
ACN 
- ESI+ 0.3 Ach: 0.05 
5-HT: 0.5 
DA: 1  
GABA: 4 
Glu: 20  
Asp: 50  
Monkey brain  
Push-pull  
sampling 
[62] 
GABA Cap-LC C-18 
(0.25?50 mm, 5 µm) 
0.1% HCOOH 
ACN 
NBD-F ESI+ 20 GABA: 49  Human CSF [61] 
D-L-Glu, -Ser, - Asp Cap-LC Chirobiotic TAG 
(0.25?170 mm) 
0.012% TFA 
MeOH 
NBD-F ESI+ 5 Glu: 660 Rat brain [104] 
GABA, Glu LC* 
(SIM) 
C-18 
(4.6?150 mm, 5 µm) 
100 mM NH4Ac 
ACN 
- APCI+ 
 
20 GABA: 10 µM 
Glu: 14 µM  
Rat brain [60] 
GABA, Glu, Arg, 
Asn, Ser, Gly, Thr, 
Ala, ?- and ?-ABA 
LC C-18  
(2.1?50 mm, 3 µm) 
0.1% HCOOH 
ACN 
PrCF ESI + 15 0.5 – 2  Rat brain MD 
 
I 
NBD-F = 7-fluoro-4-nitrobenzoxadiazole   NCI = negative chemical ionization             PrCF = propyl chloroformate 
MTBSTFA = N-(tert-butyldimethylsilyl)-N-methyltrifluoro-acetamide PCI = positive chemical ionization             MeCF= methyl chloroformate 
Marfey’s reagent = 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide Chirobiotic TAG = Teicoplanin aglycon CSP            EtCF = ethyl chloroformate 
MD = microdialysate  
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Acetylcholine 
Analytes Separation Column Eluents Derivati-
zation 
Ionization Inj.  
[µl] 
LOD (nM) Sample Ref 
Ach GC Megabore DB-5 
 
 Benzene-
thiolate 
PCI, CH4 47 Ach: 10-40 Rat brain MD [68] 
Ach Cap-LC SCX 
0.075?50 mm, 5 µm) 
25 mM NH4Ac+ 
25 mM NH4form, pH 4 
MeOH 
- ESI + 5 Ach: 0.04  Rat brain MD [72] 
Ach, Ch, iso-Ach LC SCX 
(2.1?150 mm, 5 µm) 
15 mM NH4Ac+ 
10 mM NH4form, pH 4 
ACN 
- ESI + 20 Ach: 0.01  
Ch: 0.1  
Rat brain MD [70] 
Ach LC C-18  
(2.1?100 mm, 3.5 µm) 
0.05% TFA 
ACN 
- APSI+ 20 Ach: 0.15  
LOQ 
Rat brain MD [77] 
Ach LC DuetC18/SCX  
(2.1?150 mm, 5 µm) 
25 mM NH4Ac+ 
25 mM NH4form, pH 4 
ACN 
- ESI+ 10 Ach: 0.1  Rat brain MD [74] 
Ach LC C-18, ion pair  
(2.1?50 mm, 5 µm) 
20 mM NH4form, pH 3 
0.1% HFBA 
ACN 
- ESI+ 50 Ach: 0.3  Rat brain  
MD 
[76] 
Ach, Ch LC HILIC, diol 
(4?125 mm, 5µm) 
20 mM NH4form, pH 3.3 
ACN 
- ESI + 10 Ach: 0.02  
Ch: 1  
Rat and mouse  
brain MD 
II 
Ach LC C-18 
(2.1?150 mm, 5 µm) 
20 mM NH4Ac, 
20 mM HFBA, 
MeOH 
- ESI+ 50 Ach: 0.03 Rat brain 
MD 
[63] 
Ach LC DuetC18/SCX 
(2.1?150 mm) 
32 mM NH4Ac+ 
25 mM NH4form, pH 4 
ACN 
- ESI+ 10 Ach: 0.1  Rat brain  
MD 
[73] 
SCX = strong-cation-exchange    
HFBA = heptafluorobutyric acid  
APSI = atmospheric pressure spray ionization 
Iso-Ach = (3-carboxypropyl)-trimethylammonium  
 
 
 
 
24 
Biogenic amines 
Analytes Separation Column Eluents Derivati-
zation 
Ionization Inj.  
[µl] 
LOD (nM) Sample Ref 
DA, NA, 5-HT LC C-18 
(2?150 mm,  
4 µm) 
0.1% HCOOH 
ACN 
- ESI + 10 DA: 0.2  
NA: 0.6  
5-HT: 1  
Rat brain MD [93] 
DA, 5-HT, 5-HIAA, 
HVA, DOPAC 
LC C-18 
(2.1?150 mm, 5 µm) 
0.1% HCOOH 
ACN 
- ESI+ / - 100  Rat brain  [105] 
DA, 5-HT, NA, NM LC BEH phenyl 
(2.1?100 mm, 1.7 µm) 
20 mM NH4Ac  
0.2% HCOOH 
MeOH 
Acetalde- 
hyde-d4 
ESI + 20 DA: 33 pM  
NA: 30 pM  
5-HT: 28 pM  
Rat brain MD [99] 
NA, DA, L-Tyr CapLC PGC 
(0.2?150 mm, 5µm ) 
50 mM NH4form 
MeOH 
- ESI + 2.5 NA: 3 
DA: 10 
Tyr: 30 
Rat brain [106] 
DA, DA-G, DA-3-S, 
DA-4-S, NA, A, HVA 
DOPAC 
LC PFP 
(4?150 mm, 3 µm) 
0.1% HCOOH 
ACN 
- ESI + / - 100 DA: 0.25 
NA: 5 
DOPAC: 10 
HVA: 30 
DA-G: 0.25 
DA-3-S: 0.8 
DA-4-S: 2 
Rat and mouse  
brain  
MD 
III 
5-HT, 5-HIAA, 
DOPAC, HVA and 
their sulfates and 
glucuronides 
LC PFP 
(4?150 mm, 3 µm) 
0.1% HCOOH 
ACN:MeOH 
- ESI + / - 100 5-HT: 0.1 
5-HT-G: 0.1 
5-HIAA: 1 
5-HIAA-S: 4 
DOPAC-S: 1 
HVA-S: 0.5 
Rat brain MD IV 
NM = normetadrenaline 
PGC = porous graphitic carbon 
PFP = pentafluorophenylpropyl 
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2. AIMS OF THE STUDY 
The aim of the research was to develop sensitive and specific LC-MS/MS methods for the 
analysis of neurotransmitters in rat and mouse brain microdialysates and examine their 
glucuronidation and sulfation in the brain. 
 
The more detailed aims of the research papers (I–IV) were: 
? To develop and validate quantitative LC-MS/MS methods for the analysis of 
brain microdialysates (I–IV) 
? To synthesize glucuronide and sulfate standards for method development (III, 
IV) 
? To develop direct LC-MS/MS methods for the analysis of intact glucuronide 
and sulfate conjugates (III, IV). 
? To study glucuronidation and sulfatation of neurotransmitters (DA, 5-HT) and 
their phase I metabolites (HVA, DOPAC, 5-HIAA) in the brain (III, IV). 
? To compare the effect of different derivatization reagents on the ESI efficiency 
of amino acids (I). 
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3. MATERIALS AND METHODS  
The chemicals, samples, instrumentation and analytical methods used in this work are 
briefly presented in this section. More detailed descriptions can be found in the original 
publications (I–IV). 
3.1 Chemicals 
All the chemicals used in this study were analytical or chromatographic grade. The 
structures of the compounds studied are shown in Figs 1–3, 5. 
3.2 Derivatization of amino acids 
The microdialysates and amino acid standards diluted in methanol (MeOH):H2O (1:1) or 
Ringer’s solution were evaporated to dryness (I). For propyl chloroformate (PrCF) 
derivatizations, the samples were dissolved in 80 µl of 0.1 M aqueous boric acid (B(OH)3) 
(pH 8), and 40 µl of a mixture of propanol and pyridine (4:1, v/v) and 5–10 µl of PrCF 
were added. The samples were shaken, evaporated to dryness and dissolved in eluent for 
LC-MS/MS analysis. 
 
Figure 5. Structure of derivatization products formed when test amino acids (Glu, ?-ABA, Lys 
and Thr) were derivatized with butanol, FMOC or PrCF (I). 
Derivatization with 9-fluorenylmethyl chloroformate (FMOC) was performed by adding 
100 µl of 0.1 M aqueous B(OH)3 (pH 8) and 100 µl of 12 mM FMOC (in ACN) to the 
evaporated amino acid standards. The samples were shaken and the reaction was 
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performed at room temperature (25 ?C)  for  1  h.  The  samples  were  diluted  to  a  final  
concentration of 30% ACN. 
 
Derivatization with butanol was performed by adding 200 µl of a mixture of butan-1-ol 
and acetyl chloride (4:1, v/v) to the evaporated amino acid standards. The samples were 
shaken and the reaction was performed at 70 ?C  for  1  h.  The  samples  were  then  
evaporated to dryness and dissolved in eluent for LC-MS/MS analysis. 
3.3 Synthesis of reference compounds 
The  glucuronide  and  sulfate  conjugates  of  the  neurotransmitters  and  their  phase  I  
metabolites were synthesized enzymatically or chemically for standard compounds to be 
used in the development of LC-MS/MS methods. 
3.3.1 Enzymatic synthesis of glucuronide conjugates 
The enzymatic synthesis of DA-, 5-HT-, 5-HIAA-, DOPAC- and HVA-Gs were 
performed, using microsomes prepared from rat liver (male Sprague-Dawley rats induced 
by Aroclor 1254 (a mixture of polychlorinated biphenyls)), as described previously [107]. 
The  treatment  of  the  rats  was  approved  by  the  local  Ethical  Committee  for  Animal  
Studies. The protein concentrations of the microsomes were determined with the BCA 
Protein Assay Kit (Pierce Chemical, Rockford, IL, USA). In addition to the rat liver 
microsomes (protein concentration 1 mg/ml), the incubation mixture contained 2 mM DA, 
5-HT,  5-HIAA,  DOPAC  or  HVA,  5  mM  saccharic  acid  1,4-lactone,  5  mM  UDPGA,  5  
mM MgCl2, 50 mM phosphate buffer (pH 7.4) and 2% ACN in a total volume of 30 ml. 
After incubation (37 ?C) the reaction mixture was centrifuged and the supernatants were 
purified by solid-phase extraction (SPE). The glucuronides were fractionated by LC-UV 
and lyophilized, as described in more detail in the original publications (III, IV). 
3.3.2 Enzymatic synthesis of sulfate conjugates  
The incubation mixture contained 2 mM 5-HT, 5-HIAA, DOPAC, or HVA, 100 µM 
PAPS, 10 mM phosphate buffer (pH 7.4) and 30% v/v rat liver S9 fraction (male Sprague-
Dawley rats induced by Aroclor 1254) as described previously [107]. The reaction mixture 
was incubated (37 ?C) for 2 h and 5% aqueous ZnSO4 was added (1:1, v/v). MeOH was 
added to a final concentration of 50%. After centrifugation the supernatant was purified by 
SPE and the solvent was evaporated by lyophilization. The DOPAC-Ss and HVA-S were 
fractionated by LC and the concentrations of the solutions were determined indirectly by 
determining the concentration of aglycone after acid hydrolysis by LC-MS/MS. The 
synthesis procedure is described in more detail in the original publication (IV). 
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3.3.3 Chemical synthesis of sulfate conjugates 
The chemical  synthesis  of  HVA-S,  DOPAC-Ss,  5-HIAA-S and  5-HT-S was  done,  using  
concentrated H2SO4 as described previously for DA-S [108]. The reaction mixtures were 
neutralized with 5M NaOH and the sulfates were fractionated by LC-UV, evaporated to 
dryness and lyophilized (IV). 
3.4 Analytical methods 
The  analyses  were  performed  with  an  Agilent  HP  1100  liquid  chromatograph  (Hewlett-
Packard GmbH, Waldbronn, Germany) and a PE Sciex API3000 triple-quadrupole mass 
spectrometer (Applied Biosystems/MDS Sciex, Concord, Canada) or an Agilent 6410 
triple-quadrupole mass spectrometer (Agilent Technologies, Santa Clara, USA). The more 
detailed conditions in each analysis are listed in Table 2 and the original publications (I–
IV). 
3.5 Microdialysis samples 
Male and female mice or male Wistar rats were used at 8–16 weeks of age. All procedures 
with animals were performed according to the European Community Guidelines for the 
Use of Experimental Animals (European Communities Council Directive 86/609/EEC), 
reviewed by the State Provincial Office of Southern Finland and approved by the Animal 
Experiment Board in conformance with current legislation.  
 
The animals were implanted with guide cannulae, using a stereotaxic device (Stoelting, 
Wood Dale, IL, USA) under isoflurane anaesthesia. In rats, the guide cannula was aimed 
at the nucleus accumbens, above the rat dorsal striatum or the medial prefrontal cortex 
according to the atlas by Paxinos and Watson [109]. For mice the guide cannula was 
aimed at a point above the striatum or nucleus accumbens according to the mouse brain 
atlas [110]. The cannula was fastened to the skull with dental cement (Aqualox, Voco, 
Germany) and stainless-steel screws. Buprenorphine was given for postoperative pain. The 
animals were allowed to recover for 5–7 d before the experiment.  
 
The microdialysis probe was inserted into the guide cannula of the animal the day before 
or on the morning of the experimental day. The probe was infused with Ringer’s solution 
at a flow rate of 2–2.5 ?l/min. The Ringer’s solution contained 147 mM NaCl, 1.2 mM 
CaCl2.2  H2O (Merck, Darmstadt, Germany), 2.7 mM KCl (Riedel-deHaën, Seelze, 
Germany),  1.0  mM MgCl2.6 H2O (Merck, Darmstadt, Germany), and 0.04 mM ascorbic 
acid  (University  Pharmacy,  Helsinki,  Finland)  and  was  also  used  for  the  dilution  of  
standards. The microdialysis samples were stored in a freezer (-70 ?C) before analysis 
with LC-MS/MS.  
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Table 2. Analysis conditions used in the study of different neurotransmitters by LC-MS/MS. 
The qualifier ions are shown in parentheses. 
  Gradient  Chromatographic  
Analytes SRM pairs (m/z) Time, min Org % conditions Ref. 
PrCF deriv.    
Arg 303 ? 156 (70) 0 - 10 10 - 70 
Asn 261 ? 130 (216) 10 - 12 70 
Ser 234 ? 146 (174)   
Gly 204 ? 102 (144)   
Thr 248 ? 160 (74)   
Ala 218 ? 130 (158)   
?-ABA 232 ? 144 (102)   
?-ABA 232 ? 172 (130)   
GABA  232 ? 172 (130)   
Glu 318 ? 172 (258)   
Lys 361 ? 170 (241)   
FMOC deriv.    
?-ABA 326 ? 104 (179) 0 - 10 30 - 80 
Glu 370 ? 130 (179) 10 - 12 80 
Lys 591 ? 369 (179)   
Thr 342 ? 120 (179)   
BuOH deriv.    
?-ABA 160 ? 104 (44) 0 - 10 10 - 70 
Glu 260 ? 130 (84) 10 - 12 70 
Lys 203 ? 84 (130)   
Thr 176 ? 102 (74)   
 
AtlantisTM dC-18  
(50?2.1 mm, 3 µm) 
0.1% aqueous HCOOH 
ACN 
Injection volume 15 µl 
I 
Ach 146 ? 87 0 - 3 80  
Ch 104 ? 104 3 - 3.8 80 - 65 
A-?-MeCh 160 ? 101 3.8 - 5 65 - 50 
  5 - 7.5 50 
Lichrospher diol 
(125 ? 4 mm, 5 µm) 
20  mM  NH4formate, pH 3.3, 
ACN. Injection volume 10 µl. 
II 
DA 154 ? 137 (91, 65) 0 - 10 5 - 35 
DA-S 232 ? 152 (122, 80) 10 - 10.1 35 - 80 
DA-G 330 ? 137 (154, 91) 10.1 - 13 80 
NA 170 ? 135 (107)   
A 184 ? 107 (77)   
DOPAC 167 ? 123 (95)   
HVA 181 ? 122 (74)   
Discovery HSF5  
(150 ? 4 mm, 3 µm) 
0.1% aqueous HCOOH 
ACN 
Injection volume 100 µl 
III 
5-HT 177 ? 160 (132, 117, 115) 0 - 1 5 
5-HT-G 353 ? 160 (336, 177) 1 - 11 5 - 20 
5-HT-S 257 ? 115, 160, 240 11 - 13 20 -65 
DA 154 ? 137 (91) 13 - 15 65 
DA-G 330 ? 137 (154, 91)   
5-HIAA 190 ? 146 (144, 116) 0 - 1 5 
5-HIAA-S 270 ? 226 (146, 131, 80) 1 - 11 5 - 20 
5-HIAA-G 366 ? 113, 146 11 - 13 20 - 85 
DOPAC 167 ? 123 (108, 95, 93) 13 - 15 85 
DOPAC-G 343 ? 113, 123   
DOPAC-S 247 ? 123 (203, 167, 80)   
HVA 181 ? 137 (122)   
HVA-G 357 ? 113, 123   
HVA-S 261 ? 181 (217, 80)   
Discovery HSF5  
(150 ? 4 mm, 3 µm) 
0.1% aqueous HCOOH 
ACN:MeOH (1:1) 
Injection volume 100 µl 
IV 
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4. RESULTS AND DISCUSSION 
The main results obtained in this work are described shortly in this section. More detailed 
information can be found in the original publications (I–IV). 
 
The concentrations of neurotransmitters and their metabolites in brain microdialysates are 
low (fmol amounts) and the sample volume is limited (typically < 40 µl). Many other 
endogenous compounds in addition to neurotransmitters are also extracted from the brain 
by microdialysis, and therefore the analytical method must be sensitive and specific. The 
perfusion fluid used in the microdialysis contains a high concentration of inorganic salts 
(150 mM), whereas the concentrations of small polar neurotransmitters are low, making 
demands on chromatographic separation. LC-MS/MS provides sufficient specificity and 
sensitivity for the analysis of neurotransmitters, but the inorganic salts must be separated 
from the compounds studied to provide sufficient stability and repeatability. The MS 
detection is not widely used in the analysis of neurotransmitters in the brain (Table 1) and 
the  aim  of  this  study  was  to  develop  LC-MS/MS  methods  for  the  analysis  of  different  
neurotransmitters and their metabolites in brain microdialysates.  
4.1 Analysis of amino acids 
The retention of polar amino acids on reversed-phase columns is poor and therefore ion-
pair chromatography has often been used in the analysis of amino acids by LC-MS/MS 
[111-113]. However, the ion-pair reagents decrease the ionization efficiency of the amino 
acids in ESI due to ion suppression, complicating particularly the quantitative analysis of 
GABA, whose concentration in brain microdialysate is low: 9–170 nM [47, 49, 52, 55, 56, 
58, 59]. The limit of quantification (LOQ) for GABA, using ion-pair chromatography 
connected to MS/MS was too high (100 nM, 0.5 pmol [113]) for the analysis of brain 
microdialysates. Amino acids have also been analysed with HILIC, which allows the use 
of nonsuppressive and more MS-compatible eluents, such as volatile aqueous buffers and 
ACN [114, 115], but the LODs for GABA were still too high for the quantitative analysis 
of brain microdialysates (5 µM, 50 pmol [115] or 20 nM, 6 fmol [62]). ESI sensitivity is 
not optimal for small and polar compounds, such as amino acids. It is known that the 
nonpolar properties of the compound increase the fraction of the analyte on the surface of 
the droplet formed in the ESI process [116]. The polarity of amino acids can be decreased 
by derivatization, thereby improving their ionization efficiency. The interaction of more 
hydrophobic  derivatives  with  a  reversed-phase  stationary  phase  is  stronger  and  they  are  
eluted at higher organic content, which also increases the ESI sensitivity due to lower 
surface tension, higher volatility and less efficient solvation of ions compared with highly 
aqueous eluents [117]. Separation of the signal-suppressing inorganic salts of Ringer’s 
solution from amino acid derivatives in reversed-phase chromatography is also easier than 
from native amino acids under similar conditions.  
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4.1.1 Comparison of different derivatization reagents 
Three commonly used derivatization reagents (FMOC, butanol and PrCF) were compared 
in  the  quantitative  LC-MS/MS analysis  of  amino  acids  (I).  Since  FMOC reacts  with  the  
amino group, butanol with the carboxylic acid group and PrCF with the amino, hydroxyl 
and carboxylic acid groups, amino acids with different chemical properties, such as basic 
lysine (Lys), acidic Glu, neutral ?-aminobutyric acid (?-ABA) and threonine (Thr) 
containing a hydroxyl group, were used as test compounds (Fig. 5).  
 
The reaction conditions were optimized to produce the maximal amounts of derivatization 
products. Different buffer systems were tested to optimize the PrCF and FMOC 
derivatization procedures (Fig 6). When FMOC was used, the amount of derivatization 
products was highest using 0.1 M aqueous B(OH)3,  at  pH  8.  Acidic  solvents  were  also  
tested (0.03 M hydrochloric acid (HCl) and 0.1% aqueous HCOOH), but the FMOC 
derivatization of amino acids was minimal and the derivatization products were barely 
detectable. The aqueous B(OH)3, aqueous ammonia (NH3) (pH 9.8) and 0.03 M HCl were 
advantageous in the derivatization with PrCF, with B(OH)3 working best. Different 
temperatures (70, 110 ?C) and reaction times (15–60 min) were tested in the derivatization 
with butanol and the best results were obtained when the reaction was performed at 70 ?C 
for 1 h. 
 
Figure 6. Comparison of different solvents in derivatization efficiency of Glu, ?-ABA, Thr and 
Lys by FMOC and PrCF: 0.1 M aqueous boric acid, pH 8 (B(OH)3), aqueous 
ammonia, pH 9.8 (NH3), 0.1 M aqueous ammonium acetate (NH4Ac), 0.03 M HCl and 
0.1% aqueous formic acid (HCOOH).The derivatives were analysed with LC-MS and 
the peak areas of the main products are shown. 
The derivatization reactions with butanol, FMOC and PrCF were not complete and 
partially derivatized products, in which not all the possible functional groups reacted with 
the reagent, were formed. Since PrCF can react with amino, carboxylic acid and hydroxyl 
groups, from two to four different products were formed, due to incomplete derivatization 
reactions (Fig. 7). Since FMOC and butanol react only with the amino or carboxylic acid 
groups, respectively, the number of products formed was smaller than with PrCF (one or 
two). Of amino acids tested, only acidic Glu in the reaction with butanol and basic Lys in 
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the reaction with FMOC can form more than one derivatization product. The relative 
amount of fully reacted butanol-derivatized Glu was 90% and fully reacted FMOC-
derivatized Lys 39%. For all FMOC-derivatized amino acids, a side product having a 
molecular weight one mass unit lower than that of the respective fully reacted main 
product was formed. These side products (relative amount 10–33%) were baseline-
separated from the main products and did not disturb the analysis of the main product. 
When PrCF was used the main products for ?-ABA, Lys and Glu were fully reacted amino 
acids  (relative  amount  50–98%),  in  which  all  the  reactive  functional  groups  were  
derivatized (Fig. 7). The derivatization of the hydroxyl group of Thr by PrCF was not 
favourable and in the main product only the amino and carboxylic acid groups were 
derivatized (relative amount 85%). The relative amounts of other products formed in the 
PrCF derivatizations are shown in Fig. 7. Even though many products were formed the 
repeatability of the PrCF derivatization procedure was good, the %RSD being 5–7% (n = 
6, 800 nM) for the main product (Table 3). The repeatability was 1–7% and 5–13% for the 
main products derivatized with butanol and FMOC, respectively, which was acceptable 
for bioanalysis and indicated that the repeatability of the derivatization step is good for all 
the derivatization reagents. 
 
Figure 7. Relative amounts of different products formed in the derivatization of 5 µM Glu, Lys, 
Thr and ?-ABA with PrCF. The derivatives were analysed with LC-MS in selected 
ion-monitoring mode. The m/z of the protonated products and functional groups of 
the amino acids, that reacted with PrCF are shown. 
The Ringer’s solution used in brain microdialysis contains high amounts of inorganic salts 
(>150 mM) that may affect the derivatization of amino acids. The effect of high salt 
concentration  on  the  yields  of  the  derivatization  products  was  tested  with  the  
derivatization of the test amino acids (800 nM) diluted in Ringer’s solution (Table 3). The 
comparison showed that high salt concentrations decreased the yields of the butanol 
derivatives (Glu, ?-ABA and Thr) by 4–15% and FMOC-derivatized Lys by 28%. The 
yields of the PrCF derivatives increased by 3–22% and the FMOC derivatives other than 
Lys by 0–46%. The results indicate that the derivatization procedures can also be applied 
at high salt concentrations. The repeatabilities were slightly higher for amino acids 
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derivatised in Ringer’s solution than in MeOH:H2O (1:1), (Table 3) but they were less 
than 15% (except 65% for FMOC-derivatised Lys), which is acceptable for a bioanalytical 
method. 
 
The collision-induced dissociation of four differently derivatized test amino acids was 
studied (Table 4, I). The main product ion in the MS/MS spectra of all FMOC derivatives 
was at m/z of 179 [M+H-CO2-amino acid]+.  Cleavage of the FMOC moiety (loss of 222 
Da), producing a protonated amino acid, was also common (intensity 31–39%), and the 
fragmentation continued with the loss of water for the ?-ABA, Glu, and Thr derivatives.  
The  loss  of  1-butene,  commonly  occurring  together  with  the  loss  of  water  (?-ABA, Glu 
and  Thr)  or  NH3 (?-ABA  and  Lys),  was  observed  in  the  MS/MS  spectra  of  protonated  
molecules of butanol-derivatized amino acids. The fragmentation patterns occurring after 
the loss of 1-butene were the same as those observed for underivatized amino acids [112, 
118]. The MS/MS spectra of the PrCF derivatives showed more product ions than those of 
the other derivatives. The loss of propanol (60 Da) was common for all PrCF-derivatized 
amino acids, and the fragmentation continued with the loss of carbon monoxide (Glu, Lys 
and Thr) or water (Thr). The loss of 1-propene was also observed in the MS/MS spectra of 
protonated molecules of PrCF-derivatized amino acids. 
 
The  retention  of  the  PrCF  and  FMOC  derivatives  of  the  amino  acids  in  reversed-phase  
chromatography was better than that of the butanol derivatives (Figure 2, I). The 
derivatization with butanol does not mask the amine, which is protonated under the 
chromatographic conditions used and reduces the retention of the derivatives. The 
ionization efficiency of the amino acids was significantly improved after derivatization 
(2–60 times) compared with that of native amino acids. In analysis of the derivatized 
amino acids, good repeatability (%RSD < 9%) and low LODs (0.5–2 nM, 7.5–30 fmol, 
signal-to-noise ratio (S/N) of at least 3) were observed with the PrCF and butanol 
derivatives (Table 3). The repeatabilities were similar to those of other studies in which 
the butanol and chloroformate derivatives of the amino acids were analysed with LC-ESI-
MS/MS [119, 120]. Usually the criterion for a good calibration curve is that the 
concentration of standard should not deviate from the nominal concentration by more than 
15% except at LOQ 20% deviation is accepted. The linearity did not meet the criteria at 
the lower concentration range (10-100 nM) with butanol derivatised amino acids and PrCF 
derivatised Thr, deviation <35% (Table 3). Better linearity was observed at the higher 
concentration range (0.5-8 µM) for butanol and PrCF derivatised amino acids, the 
deviation being less than 16%. Derivatization with FMOC was less suitable for the 
quantitative analysis of amino acids, due to the method’s poorer linearity (r2 = 0.925–
0.994, deviation <59%, Table 3), repeatability (%RSD < 13%) and slightly higher LODs 
(0.5–5 nM, 7.5–75 fmol) than those achieved with the other reagents. Peaks at the rts of 
the  derivatized  amino  acids  (S/N  =  2-9)  were  observed  in  the  analysis  of  the  FMOC-,  
PrCF- and butanol-derivatized blank samples, complicating the analysis of amino acids at 
low concentrations. These memory effects in the analysis of amino acids in microdialysis 
samples have also been reported previously after OPA derivatization by LC using 
amperometric detection [46, 52] and after NDA derivatization by LC-FL [51]. 
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Table 3. Validation results of the LC-MS/MS method for the analysis of derivatized test-amino acids. 
Derivatization Parameter ?-ABA Glu Lys Thr 
PrCF Retention time (min) 10.1 11.9 11.5 8.4 
 SRM pair, m/z 232 ? 172 318 ? 172 361 ? 241 248 ? 160 
 r2 (10-100 nM) (Accuracy) 0.978 (85–109%) 0.990 (87–107%) 0.992 (85–108%) 0.981 (83–112%) 
 r2 (0.5-8 µM) (Accuracy) 0.999 (86–116%) 0.999 (90–107%) 0.999 (93–108%) 0.999 (96–107%) 
 Intra-assay precision, %RSD (800 nM, n=6) 5.2 7.0 5.4 6.6 
 LOD (nM, S/N = 3) 0.5 (7.5 fmol) 2 (30 fmol) 0.7 (10.5 fmol) 1 (15 fmol) 
 Relative intensity in Ringer’s solutiona 103% 117% 103% 122% 
 Intra-assay precision, %RSD (800 nM, n=6) in Ringer 9.9 10.5 8.3 6.0 
      
FMOC Retention time (min) 7.4 6.0 11.5 6.2 
 SRM pair, m/z 326 ? 104 370 ? 130 591 ? 369 342 ? 179 
 r2 (10-100 nM) (Accuracy) 0.981 (85–134%) 0.982 (93–134%) 0.943 (85–136%) 0.963 (89–129%) 
 r2 (0.5-8 µM) (Accuracy) 0.972 (41–144%) 0.979 (73–136%) 0.925 (56–136%) 0.994 (73–123%) 
 Intra-assay precision, %RSD (800 nM, n=6) 7.9 11.4 5.3 13.2 
 LOD (nM, S/N = 3) 4 (60 fmol) 5 (75 fmol) 0.5 (7.5 fmol) 1 (15 fmol) 
 Relative intensity in Ringer’s solutiona 100% 146% 72% 115% 
 Intra-assay precision, %RSD (800 nM, n=6) in Ringer 15.3 11.5 65.1 6.6 
      
Butanol Retention time (min) 3.0 7.9 0.9 1.7 
 SRM pair, m/z 160 ? 104 260 ? 130 203 ? 84 176 ? 74 
 r2 (10-100 nM) (Accuracy) 0.994 (85–125%) 0.989 (86–135%) 0.986 (85–121%) 0.993 (90–127%) 
 r2 (0.5-8 µM) (Accuracy) 0.999 (92–104%) 0.998 (90–107%) 0.996 (92–108%) 0.999 (91–110%) 
 Intra-assay precision, %RSD (800 nM, n=6) 1.8 3.7 1.4 7.4 
 LOD (nM, S/N = 3) 1 (15 fmol) 1 (15 fmol) 1 (15 fmol) 1 (15 fmol) 
 Relative intensity in Ringer’s solutiona 96% 89% -b 85% 
 Intra-assay precision, %RSD (800 nM, n=6) in Ringer 7.0 4.5 -b 7.7 
a The relative intensity of amino acids derivatized in Ringer’s solution compared with amino acids derivatized in MeOH:H2O (1:1). 
b Butanol-derivatized Lys coeluted with the salts of Ringer’s solution and was directed to waste.  
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In the analysis of amino acids better repeatability, linearity and lower LODs were 
observed with the PrCF and butanol derivatives than for the FMOC derivatives. The 
separation of amino acids from the inorganic salts of Ringer’s solution is necessary, to 
avoid suppression effects in ESI, and this was properly achieved with the FMOC and 
PrCF derivatives, but not with the butanol derivatives. Based on the results obtained with 
the four test amino acids, PrCF seemed, of the reagents tested, to be the best derivatization 
agent for the analysis of amino acids in rat brain microdialysates. 
4.1.2 Rat brain microdialysates 
Non-specific analytical methods, such as LC-EC [47, 52], LC-FL [58] and CE-LIF [49, 
55, 56, 59], have commonly been used for the analysis of amino acids in brain 
microdialysates. A more specific LC-ESI-MS/MS technique has been used in only a few 
studies: for the analysis of amino acids sampled from monkey brain [62] and D- and L-
serine in rat brain microdialysates [103]. However, analysis of GABA in rat brain 
microdialysates by LC-MS/MS has not been presented in the literature. 
 
The suppression effect of the sample matrix on the signal intensity of the amino acid 
derivatives was studied by injecting a PrCF-derivatized rat brain microdialysis sample into 
the column and following the intensity of PrCF-derivatized ?-Alanine (?-Ala), which was 
continuously  infused  and  combined  with  the  LC  effluent  through  a  T-piece  after  the  
analytical column (Fig. 3, I). The intensity of the ?-Ala  signal  was  similar,  whether  the  
injected sample was a solvent, a PrCF-derivatized microdialysis sample or a Ringer’s 
solution blank, indicating that the microdialysate contained no signal-suppressing 
components. The rat brain microdialysates were spiked with 1000 nM arginine (Arg), 
asparagine (Asn), Ser, Gly, Thr, Ala, 100 nM Glu and 50 nM GABA, ?-ABA and ?-ABA. 
The recovery for the addition was acceptable for all amino acids tested, being between 
79% and 120% (Table 2, I), also indicating that no suppressing compounds were coeluting 
with the amino acids studied. The concentration of amino acids deviated from the added 
amount less than 15% (except of Arg (21%) and Ser (20%)), which is considered as 
acceptable accuracy for a bioanalytical method. Calibration curves for each amino acid 
were measured, and the linearity was acceptable, the r2 being 0.9851–0.9996 and deviation 
less than 15%, except in one data point for Asn (49%), Thr (23%) and Glu (29%). 
 
In  all,  ten  amino  acids  were  analysed  in  rat  brain  microdialysates  collected  from  the  
striatum by LC-MS/MS after precolumn PrCF derivatization (Fig. 8). In fact, this was the 
first time that GABA, the predominant inhibitory neurotransmitter in the brain, was 
analysed in rat brain microdialysates by LC-MS/MS. Seven microdialysis samples were 
collected at 30 min intervals and GABA was analysed in parallel with specific LC-MS/MS 
(PrCF derivatization) (I) and LC-FL  (OPA derivatization) [54]. The concentrations of 
GABA were 12–26 nM (rat 1) and 37–63 nM (rat 2) with both methods, indicating that 
GABA can be accurately quantified with LC-MS/MS and LC-FL (Table 5, I). 
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Figure 8. LC-MS/MS analysis of rat brain microdialysate derivatized with PrCF. The SRM 
pairs followed for each amino acid were m/z 303?156 for Arg, m/z 261?130 for 
Asn, m/z 234?146 for Ser, m/z 248?160 for Thr, m/z 204?102 for Gly, m/z 
218?130 for Ala, m/z 232?172 for GABA and ?-ABA, m/z 232?144 for ?-ABA and 
m/z 318?172 for Glu (I). 
GABA and its isomers ?- and ?-ABA (also extracted from the brain) were 
chromatographically separated from each other and the isomers did not interfere with the 
quantitative LC-MS/MS analysis of GABA in the microdialysates (Fig 9). Interestingly, 
the concentration of ?-ABA was  similar  to  that  of  GABA.  The  concentrations  of  amino  
acids other than the ABA isomers in brain microdialysates were 0.2–9 µM (Table 5, I). 
The concentration of Glu (0.2–0.6 µM) was lower than in other studies using CE-LIF (3–
11  µM  [49,  59])  but  the  flow  rate  of  the  perfusion  fluid,  which  affects  the  recovery  of  
amino acids,  was higher in our study (2 µl/min versus 1 µl/min [49, 59]).  
 
Figure 9. Analysis of PrCF-derivatized GABA, ?-ABA and ?-ABA by LC-MS/MS in standards 
diluted in Ringer’s solution (a) and rat brain microdialysates (b). SRM 
chromatogram of Ringer’s solution (c, blank). 
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4.2 Analysis of acetylcholine and choline  
Derivatization of amino acids was used to improve their retention in reversed-phase 
chromatography and ESI efficiency (I). Instead of derivatization, good retention for native 
neurotransmitters  can  be  achieved  using  polar  stationary  phase,  such  as  diol,  silica  or  
amine, for which polar compounds have high affinity. In HILIC the retention of polar 
compounds is increased when the proportion of organic solvent is increased and aqueous 
mobile phases usually containing more than 50% organic solvent are used. The high 
organic content in the eluent is also favourable for the sensitive ESI of analytes. HILIC 
was employed in the analysis of ionic Ach and Ch, which have minimal retention in 
reversed-phase chromatography (II). 
4.2.1 HILIC-MS/MS method development 
A diol column was used for the LC-MS/MS analysis of Ach and Ch in brain 
microdialysates (II). The analysis was carried out using 80% ACN in the eluent. The 
buffer concentration (10, 20 or 30 mM aqueous ammonium formate) clearly affected the 
elution of chloride ions in Ringer’s solution (measured as an ammonium chloride cluster 
at m/z 338 [(NH4Cl)6NH4]+) and also on the peak width of Ach and Ch (Fig. 10). The 
lower the buffer concentration, the broader was the elution band of chloride ions. The 
coelution of chloride ions with Ach and Ch increased the theoretical plate numbers of the 
analytes, but also caused ion suppression and decreased sensitivity. The best sensitivity 
was obtained under conditions in which the chloride ions were only slightly separated 
from Ach (20 mM buffer). The chloride ions coeluted with Ch under all separation 
conditions tested. The ion suppression caused by chloride ions in Ch ionization did not 
interfere with the quantitative analysis, since the concentration of Ch in brain 
microdialysates is high (at µM the level). However, the chloride ions caused corrosion of 
the stainless-steel union of the ion source. When the parts were changed to a more inert 
alternative (Hastelloy C?, nickel-chromium-molybdenum alloy), the analysis could be 
carried out for weeks without the clogging caused by corrosion. Clogging of the MS 
interface was previously reported when microdialysis samples were analysed with LC/MS 
[121]. The cations of Ringer’s solution were well separated from the analytes and were 
washed into the waste after elution of Ch (II). 
 
Due to the high organic content in the eluent (80%), low LODs  (S/N = 3) of 0.02 and 1 
nM (0.2 and 10 fmol) were achieved for Ach and Ch, respectively (II). Even lower LODs 
for Ach were achieved in later studies employing HILIC-MS/MS by decreasing the 
column diameter [62, 71]. LODs of 0.05 nM (0.015 fmol) [62] and 0.0075 nM (0.075 
fmol)  [71]  for  Ach  were  reported,  using  0.2  and  2.1  mm  internal  diameter  (i.d.)  HILIC  
columns, respectively. Low LODs of 0.01 nM (0.2 fmol, column i.d. 2.1 mm) [70] and 
0.04 nM (0.012 fmol, colum i.d. 0.075 mm) [72] were also achieved, using smaller 
diameter cation exchange columns. Even though Ringer’s solution is a strong solvent in 
HILIC, the brain microdialysates could be injected as such in this study (II). In other 
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HILIC separation systems, dilution of the samples with organic solvent was needed [62, 
71]. The between-day repeatability (%RSD 3.1–3.5%) and linearity of the method was 
good, with r of 0.999 (0.1–50 nM, deviation <5%) and 0.998 (0.1–3.5 µM, deviation 
<15%) for Ach and Ch, respectively (II). 
 
Figure 10. LC-MS extracted ion chromatograms of 1 nM Ach (m/z 146), 500 nM Ch (m/z 104), 5 
nM ISTD (m/z 160)  and chlorides (m/z 338 [(NH4Cl)6NH4]+) measured using 10, 20 
and 30 mM ammonium formate (pH 3.3) buffer : ACN (20:80) (II). 
4.2.2 Rat and mouse brain microdialysates 
In the analysis of Ach and Ch, acetyl-?-methylcholine  was  used  as  an  ISTD  (II).  It  is  
known that endogenous compounds with the same mass transitions as Ach (m/z 146?87) 
and  ISTD  (m/z 160?101) are coextracted from the mouse brain [63, 70]. Both of the 
endogenous compounds were well separated from Ach and the ISTD and did not disturb 
the analysis in our study (Fig. 11). The concentration of Ach in brain microdialysates is 
low, and therefore blank samples (pure Ringer’s solution) were analysed to study a 
possible carry-over effect. The selected reaction monitoring (SRM) chromatogram (m/z 
146?87) of a blank sample showed no signals at the rt of Ach. However, a peak (S/N = 
2.5) at the rt of Ch was observed in the SRM chromatogram (m/z 104?104), but the peak 
height of Ch in brain microdialysate was much higher (500 times) and the quantitative 
analysis was not compromised. The rat brain microdialysates were spiked with 1 or 2.5 
nM Ach and 0.2 or 1 µM Ch. The recovery for the addition was acceptable (90–101%), 
indicating that no suppressing compounds were coeluting with Ach and Ch and accuracy 
of the method is good. We observed that Ch decomposed totally in the brain 
microdialysate samples stored at room temperature for 24 h, while it was stable for at least 
three days when stored in the freezer (-20 ?C). However, no decomposition of Ch diluted 
in Ringer’s solution and stored at room temperature for three days was observed. These 
results indicate that the microdialysis samples should be analysed or frozen immediately 
after collection and thawed just before the analysis. Ach was stable for 72 h, whether the 
microdialysis sample was stored at room temperature or in the freezer. 
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Figure 11. SRM chromatograms of a mouse brain microdialysate collected from the nucleus 
accumbens with an acetyl-?-methylcholine ISTD addition. 
This was the first time that HILIC-MS/MS was employed in the analysis of Ach and Ch in 
brain microdialysates (II). The concentrations measured for Ach in the rat and mouse brain 
microdialysates were at least eight times higher than the LOQ, indicating that the method 
can potentially be used for reliable analysis of Ach in brain microdialysis samples without 
the use of acetylcholinesterase inhibitors. 
4.3 Analysis of biogenic amines and their phase I and II 
metabolites 
Sulfation and glucuronidation of neurotransmitters and phase I metabolites in the brain has 
usually been studied by indirect analytical methods employing acidic or enzymatic 
hydrolysis.  The  indirect  analytical  methods,  however,  are  prone  to  errors  due  to  the  
hydrolysis step, which also complicates the analysis. Even though the type of conjugate 
can be investigated with greater certainty after specific enzymatic than after acidic 
hydrolysis, the presence of the conjugate is still difficult to confirm by indirect methods, 
especially if the concentration of conjugate is low compared with that of free aglycone. 
The differentiation of separate regioisomers of glucuronide and sulfate conjugates is also 
impossible with indirect methods employing hydrolysis. One reason for the use of indirect 
methods is the lack of commercial sulfate and glucuronide standards. The sulfate and 
glucuronide conjugates of DA, HVA, DOPAC, 5-HT and 5-HIAA were chemically and/or 
enzymatically synthesized to provide authentic reference compounds for a direct LC-
MS/MS method (III, IV).  
4.3.1 Enzymatic synthesis of glucuronides  
The  glucuronides  of  DA,  5-HT,  5-HIAA,  HVA  and  DOPAC  were  synthesized  
enzymatically, using rat liver microsomes as a biocatalyst (III, IV). The chromatographic 
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separation of different regioisomers of the glucuronide conjugates was achieved with a 
pentafluorophenylpropyl (PFP) column. LC-MS extracted ion chromatograms of the 
deprotonated molecules showed one peak for 5-HT-G, two peaks for 5-HIAA-Gs, and four 
peaks for DOPAC-Gs and HVA-Gs. Two regioisomers of DA-Gs were produced, but the 
intensity of the minor glucuronide product was only 1% of the main product peak. 
Abundant [M-H]- corresponding to mono glucuronidated compounds was observed in the 
negative ion mass spectra of DA-G, 5-HT-G, 5-HIAA-Gs, HVA-Gs and DOPAC-Gs and 
[M+H]+ in the positive ion mass spectra of DA-G and 5-HT-G. The respective negative 
ion MS/MS spectra showed product ions at m/z 175 [M-H-aglycone]-, m/z 157 [M-H-
aglycone-H2O]- and m/z 113 [M-H-aglycone-H2O-CO2]- derived from the glucuronic acid 
moiety, confirming the presence of the glucuronic acid moiety in the molecule (Fig 12). 
The glucuronidation site of 5-HT-G and DA-G was determined by nuclear magnetic 
resonance (NMR) spectroscopy. Heteronuclear multiple bond correlation (HMBC) 
experiment showed 3J coupling of the acetal CH proton (H1’) to the quaternary aromatic 
carbon ArCO (C5), indicating that the glucuronide group is attached to the phenolic 
oxygen of 5-HT. In a previous study it was also shown that the glucuronidation of 5-HT 
with mouse liver microsomes occurred at the phenol group [86]. The 1H NMR analysis 
showed that the main product formed in the synthesis of DA-G was glucuronidated at the 
4-position, because the chemical shift that was most strongly moved downfield in DA-G 
compared with DA was that of aromatic H5. 
 
Figure 12. LC-ESI-MS/MS analysis of enzymatically synthesized DA-G, 5-HT-G, 5-HIAA-G, 
DOPAC-G and HVA-G. The product ion chromatograms and most abundant (>10%) 
m/z values in the MS/MS spectrum of [M-H]- is shown. For 5-HT-G and DA-G, the 
m/z values in the product ion spectrum of [M+H]+ are also shown (III, IV).Linear 
gradient 5–35% ACN:MeOH(2:1) for 0-10 min was used. 
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The recovery for the glucuronides of the phase I metabolites (HVA, DOPAC and 5-HIAA) 
was too low to study their structure by NMR and therefore only negative ion MS/MS 
spectra were used for the identification. A product ion at m/z 193 (glucuronic acid) was 
observed in the MS/MS spectra of three HVA-Gs (rts 6.65, 7.20 and 7.35 min), two 
DOPAC-Gs (rts 5.18 and 5.76 min) and one 5-HIAA-G (rt 7.31 min) (Fig 12). It was 
previously reported that in the MS/MS spectra of aliphatic hydroxyl glucuronides, a 
product ion at m/z 193 is observed, whereas it is not observed in the MS/MS spectra of 
phenol-linked glucuronides [122-124]. Therefore it is reasonable to assume that those 
HVA-Gs,  DOPAC-Gs  and  5-HIAA-G  showing  a  product  ion  at  m/z 193 in the MS/MS 
spectra were glucuronidated to the carboxylic group, producing acyl glucuronides. The 
DOPAC-Gs (rts 6.23 and 6.47 min), HVA-G (rt 6.79 min) and 5-HIAA-G (rt 6.56 min) 
were most probably glucuronidated at the phenolic groups since m/z 193 was not observed 
in the MS/MS spectra. However, the glucuronidation site cannot be confirmed with 
certainty by MS/MS studies. 
4.3.2 Enzymatic synthesis of sulfates 
DOPAC-, HVA, 5-HT- and 5-HIAA-Ss were synthesized enzymatically, using the rat 
liver S9 fraction and analysed by LC-MS (IV). One monosulfated product was observed 
for 5-HT, 5-HIAA and HVA, while two monosulfated products were formed for DOPAC. 
The product ion spectra of 5-HT-S, DOPAC-Ss and HVA-S showed the loss of sulfur 
trioxide (80 Da), producing the free substrate and clearly indicating the presence of the 
sulfate moiety in the molecule (Fig. 13). The loss of substrate producing a product ion at 
m/z 80  was  observed  in  the  MS/MS  spectra  of  5-HT-S,  5-HIAA-S  and  HVA-S.  The  
product ion spectrum of [M-H]- of 5-HIAA-S, DOPAC-Ss and HVA-S showed abundant 
product ions at m/z 226, m/z 203 and m/z 217, respectively, formed by the direct loss of 
carbon dioxide (44 Da) from the [M-H]- ion and indicating that sulfate is not attached to 
the carboxylic acid group of the substrate. It is known that the hydroxyl group is a 
common acceptor group of sulfate in the reaction catalysed by SULT [125], and therefore 
the most obvious sulfatation site is a phenolic hydroxy group. However, the yield of 
sulfates in the enzymatic synthesis was too low to study the conjugation site by NMR and 
therefore chemical synthesis was applied. 
4.3.3 Chemical synthesis of sulfates 
Chemical synthesis yielded one monosulfated main product for HVA and 5-HT, while two 
different monosulfated 5-HIAA-Ss and DOPAC-Ss were formed (Fig. 13). The two 
DOPAC-S isomers are almost coeluting in Fig. 13 (eluents ACN:MeOH (1:1), 0.1% 
aqueous HCOOH), but they were baseline-separated when a different eluent system was 
used (ACN, 0.1% aqueous HCOOH). Identical products having similar rts and MS/MS 
spectra were formed in the chemical and enzymatic synthesis of 5-HT-S and 5-HIAA-S (rt 
9.64 min). The rts and MS/MS spectra of chemically synthesized DOPAC-Ss and HVA-S 
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differed from those that were enzymatically synthesized, indicating that the structures of 
the products are different. The yield of sulfates in the chemical synthesis was sufficient for 
NMR studies (over 2 mg). The chemical shifts of the H4 and H6 protons of 5-HT-S and 5-
HIAA-S (rt 9.64 min) were clearly moved downfield, compared with those of free 
substrates, indicating that sulfation occurred at the phenolic group. NMR studies of 
chemically synthesized DOPAC-Ss and HVA-S showed that only two aromatic hydrogens 
were seen in the spectrum, suggesting that sulfation had occurred in the benzene ring. 
However, similar chemical synthesis has been successfully used for the production of DA-
3- and 4-O-Ss [108]. 
 
Figure 13. LC-ESI-MS/MS analysis of enzymatically and chemically synthesized 5-HT-, 5-HIAA- 
DOPAC- and HVA-sulfates. The negative ion MS/MS spectrum for each 
chromatographic peak is shown (IV). Linear gradient 5% ACN:MeOH (1:1) for 1 min 
and 5–20% ACN:MeOH (1:1) for 1-11 min was used. 
In the analysis of brain microdialysates chemically synthesized 5-HT-S and 5-HIAA-S (rt 
9.6 min) and enzymatically synthesized DOPAC-Ss and HVA-S were used as standards. 
The production of HVA-S and DOPAC-Ss on the milligramscale with enzymatic synthesis 
was not successful and therefore the concentrations of solutions containing HVA-S and 
DOPAC-S were calculated by determining the concentration of free HVA and DOPAC by 
LC-MS/MS after acid hydrolysis. 
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4.3.4 Rat brain microdialysates 
The retention of biogenic amine neurotransmitters and their phase I and II metabolites in 
the reversed-phase chromatography is minimal. Use of the more polar PFP stationary 
phase provided adequate retention and also the separation of different regioisomers of 
intact glucuronide and sulfate conjugates (Figs. 12–15). The inorganic salts of Ringer’s 
solution were eluted well before the analytes and were washed to waste. The LODs (S/N = 
3) for polar biogenic amines and their glucuronides analysed in the positive ion mode 
varied between 0.1 and 0.3 nM (10–30 fmol). Intact 5-HT-G and DA-G have not 
previously been analysed by LC-MS/MS, but the LODs for DA and 5-HT determined by 
LC-ESI-MS/MS have been reported to vary between 0.2 and 10 nM (2–25 fmol injected 
into the column) [93, 106]. In a recent study, lower LODs (30 pM, 0.6 fmol) for DA and 
5-HT by UPLC?-MS/MS was achieved after derivatization [99]. The LODs (0.5-20 nM, 
50–2000 fmol) were higher for negatively charged HVA, DOPAC, 5-HIAA and their 
sulfate  conjugates,  but  the  sensitivity  was  adequate  for  the  measurement  of  brain  
microdialysates. Similar LODs for HVA and DOPAC were reported in a previous study, 
using LC-MS/MS [126]. The calibration curve for each compound was measured (Tables 
1 and 3, III and IV, respectively), and the linearity was good, r2 being > 0.996 and 
deviation less than 15%, except in few data points <29%. The intra-assay precision of the 
method was studied at two concentration levels: 10 and 100 nM. The %RSD values were 
typically  below 4%,  indicating  good repeatability  of  the  analysis.  The  matrix  effect  was  
studied by spiking brain microdialysates with 2.7 nM DA and DA-G, and 91 nM HVA 
and DOPAC (III). The recoveries were <111% for DA and HVA, which is acceptable for 
a  bioanalytical  method,  while  the  recovery  was  119% for  DA-G and 81  % for  DOPAC.  
The effect of matrix on ionization of 5-HT, 5-HT-G, 5-HIAA, 5-HIAA-S, HVA-S and 
DOPAC-S was not studied, and therefore possible suppression effects may distort the 
quantification of these compounds. Decomposition of DOPAC in brain microdialysates 
was observed. Six injections were made from a pool of microdialysates collected from the 
striatum of mouse brains and the concentration of DOPAC decreased from 290 nM to 90 
nM during the 4 h storage of the brain microdialysis sample at room temperature, resulting 
in poor repeatability (%RSD = 37%). However, the concentration of DOPAC (500 nM) 
diluted in Ringer’s solution (standard sample), stored at room temperature and analysed at 
1, 13, 26, 36 and 51 h after sample preparation, remained constant (%RSD 2.5%). These 
results indicate that microdialysate samples should be analysed or frozen immediately 
after collection to prevent this decrease in concentration of DOPAC.  
 
For the quantitative analysis of rat brain microdialysates the injection volume needed to be 
high (100 µl) and therefore the rapid changes in neurotransmitter levels in the brain could 
not  be  measured  (III,  IV).  However,  the  LC-MS/MS  method  was  well  suited  for  
measuring the levels of glucuronides and sulfates of neurotransmitters and their phase I 
metabolites, as well as the unconjugated analytes in the brain microdialysates. The 
compounds were detected by comparing the rts and the intensity ratios of at least two 
SRM pairs of each compound in brain microdialysates with those of the standards diluted 
in Ringer’s solution. The variation in the intensity ratio of the product ions monitored was 
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less than 15% and the variation in the relative rts was less than 1.3% in all positive 
identifications. The SRM chromatograms of the blank Ringer’s solution, run before every 
microdialysis sample, showed no memory effects. 
 
 
 
Figure 14. SRM chromatograms of (A) 5 nM 5-HT and 5-HT-Glu, and 100 nM 5-HIAA and 5-
HIAA-sulfate standards diluted in Ringer’s solution, (B) rat brain microdialysate and 
(C) Ringer’s solution (blank) (IV). The chromatographic conditions are shown in 
Table 2. 
For the first time, the intact glucuronide conjugates of DA and 5-HT were unambiguously 
detected in rat brain microdialysates (Figs. 14 and 15) (III, IV). The concentration of 5-
HT-G (1.0–1.7 nM) was over two times higher than the concentration of 5-HT (0.4–2.1 
nM) in three out of four rat brain microdialysates analysed (Table 4). For DA the 
concentration of glucuronide conjugate (1.0–1.4 nM) was similar or lower than the 
concentration of free neurotransmitter (1.2–2.4 nM). In previous studies an acid-
hydrolysable conjugate of 5-HT was detected in superfusates of rat spinal cord [80], but 
the glucuronidation of 5-HT has not been shown. 5-HT is a good substrate for UGT 1A6 
[20], which is expressed in human [20] and rat brain [19], supporting the presence of 5-
HT-G in rat brain microdialysates found in the present study (IV). DA-G was found in rat 
[22]  and  human  [23]  CSF,  which  is  assumed  to  reflect  the  metabolism  of  
neurotransmitters in the brain. The glucuronides of 5-HIAA, DOPAC or HVA in rat brain 
microdialysates were not detected in our study (IV). 
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Figure 15. SRM chromatograms of (A) 5 nM DA and DA-Glu, 300 nM DOPAC and HVA, 360 nM DOPAC-sulfate and 100 nM HVA-sulfate standards 
diluted in Ringer’s solution, (B) rat brain microdialysate, and (C) Ringer’s solution (blank) (IV). The chromatographic conditions are shown 
in Table 2. 
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Table 4. Analytical results of rat brain microdialysates by LC-MS/MS. 
 Concentration, nM 
Compound Animal 1 Animal 2 Animal 3 Animal 4 
5-HT 0.4* 0.5 0.7 2.1 
5-HT-G 1.0 1.3 1.7 1.5 
5-HIAA 110 140 120 150 
5-HIAA-S 7* 11* 12* 13* 
DA 1.2 2.0 2.4 2.1 
DA-G 1.1 1.4 1.0 1.0 
DOPAC 890 910 700 980 
DOPAC-S (rt = 6.6 min) 40 40 40 40 
DOPAC-S (rt = 7.0 min) 280 290 280 400 
HVA 510 510 360 540 
HVA-S 90 90 80 100 
* < LOQ, only an estimation 
 
 
The rat brain microdialysate analysed with LC-MS/MS contained 5-HIAA-S, HVA-S and 
two DOPAC-S regioisomers, most probably DOPAC-3- and -4-O-S (Fig. 14). The 
sulfation of DOPAC, HVA and 5-HIAA in rat brain has also been observed in previous 
studies, where a clear increase in the concentration of free substrate after enzymatic 
sulfatase hydrolysis was observed [27, 28]. We observed that app. 10%, 15% and 30% of 
5-HIAA, HVA and DOPAC, respectively, was in sulfated form in rat brain striatum 
microdialysates (Table 4). In other studies the conjugated phase I metabolites were 
extracted from brain samples, and the amounts of conjugated 5-HIAA, HVA and DOPAC 
after acid hydrolysis were 10%, 20–36% and 12–32%, respectively, of the total amount 
(concentration of conjugated and free substrate) in the rat brain striatum [78, 79, 127]. 
These concentration ratios are quite similar to those obtained in our study in 
microdialysates collected from the rat brain striatum (IV). Neither DA-S (LOD 0.8 nM, 80 
fmol) nor 5-HT-S (LOD 0.1 nM, 10 fmol) was detected in rat brain microdialysates (III, 
IV), even though DA-S was detected in rat CSF [22] and brain samples [26] after sulfatase 
hydrolysis. In a previous study the sulfate conjugates of 5-HT and DA were detected in 
human CSF [23]. 
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5. SUMMARY AND CONCLUSIONS 
The concentration of neurotransmitters and their metabolites in brain microdialysates is 
low (fmol amounts) and the sample volume is limited (typically < 40 µl). The capability 
for  analysing  small  sample  volumes  is  desired  so  that  the  chemical  changes  in  the  brain  
can be monitored over short time intervals. The perfusion fluid used in the microdialysis 
contains a high concentration of inorganic salts (150 mM), whereas the concentration of 
small polar neurotransmitters is low, making demands on chromatographic separation. 
Many compounds having similar structures are coextracted from the brain, which 
complicates method development even with specific LC-MS/MS. Low LODs and good 
specificity are required of the analytical method to be able to analyse low concentrations 
of neurotransmitters accurately and therefore triple-quadrupole instruments and SRM 
mode was selected for the detection in this study. LC-MS/MS methods were developed for 
the  analysis  of  neurotransmitters  and  their  phase  I  and  phase  II  metabolites  in  the  brain  
microdialysates. Another aim of this study was to identify glucuronide and sulfate 
conjugates of neurotransmitters in the brain. However, fully validation of the methods was 
not performed and in future applications it should be done to ensure the reliability of 
quantitative results. 
 
The sensitivity of ESI-MS analysis is not optimal for small polar compounds. In the 
present study the ionization efficiency of polar amino acids was improved by converting 
the polar nature of amino acids to a more hydrophobic by derivatization. Retention in 
reversed-phase chromatography was increased and the amino acid derivatives were eluted 
at  higher  organic  contents,  which  also  enhanced  ESI  sensitivity.  The  LODs  for  amino  
acids derivatized with FMOC, PrCF or butanol were 2–60 times lower than for native 
underivatized amino acids. The separation of amino acids from the suppressive inorganic 
ions of Ringer’s solution was also achieved by FMOC and PrCF derivatization. The 
analysis of GABA in rat brain microdialysates by LC-MS/MS has not been presented 
previously,  due  to  high  LODs.  After  the  PrCF  derivatization  used  in  this  study,  GABA  
could be easily quantified in rat brain microdialysates by LC-MS/MS. The separation of 
GABA from its isomers ?-and ?-ABA, also extracted from the brain, was achieved. The 
drawback of the LC-MS/MS method developed was the memory effect observed for some 
amino acids, complicating analysis at low concentrations. 
 
The separation of polar compounds in reversed-phase chromatography requires either 
derivatization of the analyte or ion-pair additives in the eluent. However, the derivatization 
increases sample pretreatment and ion-pair reagents cause signal suppression in ESI. A 
good alternative is the use of polar stationary phases in which the polar analytes have 
higher affinity. In HILIC the compounds are eluted at high organic content, which 
increases the ESI sensitivity. Low LODs were achieved for Ach and Ch in present study, 
using  HILIC-LC-MS/MS.  The  concentration  of  Ach  in  rat  and  mouse  brain  
microdialysates, without the use of acetylcholinesterase inhibitors, was clearly above the 
LOQ with the LC-MS/MS method developed. Those compounds having the same 
molecular weight and collision induced dissociation as Ach and the ISTD, were 
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chromatographically separated. This was the first time that HILIC was employed for the 
analysis of Ach in brain microdialysates and thereafter it has also been exploited in other 
publications discussing the analysis of brain microdialysate by LC-MS/MS. The clogging 
of the MS interface observed in this study was reduced by changing the stainless-steel 
union of the ion-source to a more inert alternative but clogging might still be a problem in 
routine analysis. Therefore the method should be modified so that the entry of chloride 
ions to MS is prevented. 
 
So far indirect methods, employing either acid or enzymatic hydrolysis, have been used in 
the analysis of sulfate and glucuronide conjugates in the brain. Indirect methods are prone 
to errors, due to the hydrolysis step, and the presence of conjugate is difficult to confirm, 
especially if the concentration of conjugate is low compared with that of free aglycon. 
Even though the type of conjugate can be studied with more specific enzymatic 
hydrolysis, the conjugation site cannot be identified. In the present study, direct 
quantitative LC-MS/MS methods for the analysis of intact sulfate and glucuronide 
conjugates in brain microdialysates were developed. With a direct method even low 
concentrations of sulfate and glucuronide conjugates were measured and the different 
regioisomers were also separated. Using MS/MS detection, estimations of the 
glucuronidation site (aliphatic versus phenol-linked glucuronides) could be presented. A 
large injection volume (100 µl) was needed to be able to quantify 5-HT-G and DA-G in 
rat brain microdialysates. However, the quantification of analytes in smaller sample 
volumes is required for the follow-up of rapid changes in the concentration levels of the 
compounds in the brain. One strategy for the development of a more sensitive method for 
the analysis 5-HT, DA and their metabolites may be the use of miniaturized LC-MS/MS 
systems 
 
In our study the glucuronidation of 5-HT and DA in rat brain was shown for the first time. 
The results suggested that neurotransmitters are glucuronidated and their phase I 
metabolites are rather sulfated. Further studies are needed to determine the meaning of this 
metabolism in the brain. What happens to the conjugates? Do they accumulate in the brain 
or do they use transporters? Can glucuronides be hydrolysed back to active 
neurotransmitters? What specific enzymes are expressed in the brain and produce these 
sulfate- and glucuronide-conjugates. Pharmacological experiments are needed to 
determine whether the concentrations of phase II metabolites are altered in different 
diseases compared with normal basal levels and what effect different drugs have on phase 
II metabolites. What happens if the phase II metabolism pathway is blocked in the brain? 
It is known that metabolic pathways may differ greatly between species and therefore it is 
highly important to explore what occurs in the human brain. SULT 1A3, found in human 
but not in rat brain, has high affinity for DA. Does the glucuronidation of DA still occur in 
human brain or is the sulfation more favourable phase II metabolism reaction?  
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